Tuberculosis, Pulmonary

Infectious Disease·MeSH: Tuberculosis, Pulmonary

Prevalence

30.0 / 100K

10 drugs in development·4 companies·6 clinical trials

Drug Pipeline by Phase

Phase 2(10)

Drug	Company
Bedaquiline	Crinetics Pharmaceuticals, Inc. (CRNX)
Clofazimine	Crinetics Pharmaceuticals, Inc. (CRNX)
Delamanid	Crinetics Pharmaceuticals, Inc. (CRNX)
Ethambutol	Crinetics Pharmaceuticals, Inc. (CRNX)
h56	HWH International Inc. (HWH)
H56	Applied Therapeutics, Inc. (APLT)
H56	Valneva SE (VALN)
Isoniazid	Crinetics Pharmaceuticals, Inc. (CRNX)
Pyrazinamide	Crinetics Pharmaceuticals, Inc. (CRNX)
Rifampin	Crinetics Pharmaceuticals, Inc. (CRNX)

BioSniper tracks 10 drugs in development for Tuberculosis, Pulmonary across 4 companies.

There are 6 clinical trials targeting Tuberculosis, Pulmonary tracked by BioSniper.

The estimated prevalence of Tuberculosis, Pulmonary is approximately 30.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.